Table 3 Reduction (%) in HIV incidence rate at 4 years compared to the baseline rate for an increased coverage of ART, VMMC and PrEP in different combinations
From: Combined interventions to reduce HIV incidence in KwaZulu-Natal: a modelling study
No PrEP | + PrEP 15–24 years: 40% 25–34 years: 0% 35–59 years: 0% | + PrEP 15–24 years: 20% 25–34 years: 0% 35–59 years: 0% | + PrEP 15–24 years: 15% 25–34 years: 10% 35–59 years: 5% | |
|---|---|---|---|---|
No changea | 24% | 32% | 28% | 28% |
ART at CD4<500 at | ||||
15–24 years: 55% | ||||
25–34 years: 75% | ||||
35–59 years: 85% | ||||
+ Baseline VMMC | 30% | 38% | 34% | 34% |
15–24 years: 26% | ||||
25–34 years: 21% | ||||
35–59 years: 19% | ||||
+ Increased VMMC at | 34% | 41% | 37% | 37% |
15–24 years: 70% | ||||
+ Increased VMMC at | 31% | 39% | 35% | 35% |
15–24 years: 35% | ||||
25–34 years: 25% | ||||
35–59 years: 20% | ||||
ART for all at | ||||
15–24 years: 50% | ||||
25–34 years: 70% | ||||
35–59 years: 80% | ||||
+ Baseline VMMC | 36% | 43% | 40% | 39% |
15–24 years: 26% | ||||
25–34 years: 21% | ||||
35–59 years: 19% | ||||
+ Increased VMMC at | 39% | 46% | 42% | 42% |
15–24 years: 70% | ||||
+ Increased VMMC at | 37% | 44% | 40% | 40% |
15–24 years: 35% | ||||
25–34 years: 25% | ||||
35–59 years: 20% |